Cowen to host conference call to discuss third quarter financial results on Friday, October 29. Click here for more information.

$135 Million

CTI BioPharma

Sole Placement Agent and Financial Advisor, August 2021

Senior Term Loan & Revenue Participation Right (Synthetic Royalty) Sale

CTI BioPharma (CTI) is a biopharmaceutical company focused on the acquisition, development and commercialization of novel targeted therapies for blood-related cancers that offer a unique benefit to patients and their healthcare providers. CTI concentrates its efforts on treatments that target blood-related cancers where there is an unmet medical need. In particular, CTI focuses on developing and commercializing Pacritinib, its product candidate currently in active late-stage development, for the treatment of adult patients with myelofibrosis, and in response to the COVID pandemic, severe COVID-19 disease. CTI is headquartered in Seattle, Washington

More Like This

Sep 2021

Financing for the acquisition of Meona and i-SOLUTIONS

Debt Advisor

View Details
Aug 2021
$316.25 Million
Alphatec Holdings

0.75% Senior Convertible Notes Offering

Bookrunner

View Details
Jul 2021
$584.78 Million

Follow-on Offering

Bookrunner

View Details